Veeva Systems Inc.
Veeva Systems Inc. (VEEV)
Overview
Veeva Systems is a cloud-computing company that builds industry-specific software, data, and consulting services exclusively for the life sciences industry — pharmaceutical, biotechnology, and medical device companies. Headquartered in Pleasanton, California, and founded in 2007 by Peter Gassner and Matt Wallach, Veeva went public in October 2013 and later became the first publicly traded company to convert to a Delaware public benefit corporation, in February 2021. The company classifies as part of the Health Information Services industry within Healthcare, generates roughly $2.7-3.1 billion in annual revenue, employs about 7,900 people, and serves well over 1,000 customers globally, including most of the world's largest pharmaceutical and biotech companies (Novartis, Bayer, Eli Lilly, Merck, Gilead, and others).
What They Do & How They Make Money
Veeva's business model is subscription-based software-as-a-service (SaaS): customers pay recurring subscription fees for access to Veeva's cloud applications, which manage the highly regulated, document-intensive workflows unique to life sciences — everything from tracking a drug through clinical trials and regulatory submission to managing sales-rep interactions with doctors and ensuring manufacturing quality compliance. In addition to subscription revenue (the large majority of total revenue and the focus of investor attention because of its high margins and recurring nature), Veeva earns professional services and other revenue from implementation, consulting, and training work that helps customers deploy and configure its software. Because life sciences companies operate under strict regulatory requirements (FDA and other global regulators), switching costs are high once a company's workflows and validated processes are built around Veeva's platform, which supports high renewal rates and predictable, recurring revenue growth.
Business Segments
Veeva organizes its products into three cloud platforms, which map to how the company discusses its business (though its formal financial reporting segments are Commercial Solutions and R&D Solutions, plus revenue is also broken out as Subscription services vs. Professional services and other):
- Commercial Cloud (Commercial Solutions) — Software for sales, marketing, and medical affairs teams, anchored by Veeva Vault CRM Suite (the customer relationship management system pharma reps use to manage interactions with physicians), along with Veeva Medical (multichannel content/medical affairs), PromoMats (marketing asset management and compliance review), and Crossix (marketing analytics measuring patient and prescriber outcomes). This has historically been Veeva's largest and most mature segment.
- Development Cloud / R&D Solutions — Software supporting the drug development lifecycle: Vault Clinical Platform and Clinical Data Management (clinical trial operations and data), Vault Safety (pharmacovigilance/adverse event tracking), Vault RIM (regulatory information management), and Vault Quality (quality management systems for manufacturing compliance). This segment has been Veeva's fastest-growing area and is viewed as its biggest long-term growth driver as it displaces legacy on-premise systems from competitors like Oracle and IQVIA-related tools.
- Data Cloud — Reference and analytics data products including OpenData (customer/prescriber master data), Link (deep organizational data), and Compass (patient-level data), which are often sold alongside Commercial or R&D applications to enhance them.
Veeva does not break out precise segment-level revenue and profit dollar splits in most public summaries, but subscription services consistently represent roughly 80%+ of total revenue, with professional services making up the remainder; overall operating income was about $691 million in fiscal 2025 on revenue of about $2.75 billion, with margins expanding meaningfully in recent years.
Competitors
Veeva's competitive landscape varies by product line:
- CRM / Commercial Cloud: Historically, Veeva's CRM ran on the Salesforce platform, but Veeva ended that partnership and moved to its own Vault platform; Salesforce (and Salesforce-based competitors) is now a more direct competitor in life sciences CRM, along with smaller specialized vendors.
- R&D / Clinical & Regulatory: Competitors include Oracle (clinical trial and safety systems), IQVIA (contract research and data/technology services), Medidata (a Dassault Systèmes company, clinical data platforms), and various point solutions for regulatory and quality management.
- Data & Analytics: IQVIA is a major competitor in life sciences reference data and commercial analytics.
- More broadly, large horizontal enterprise software vendors (Microsoft, SAP) and specialized life-sciences IT vendors compete for pieces of Veeva's addressable market, though few offer Veeva's breadth across the entire commercial-to-R&D value chain purpose-built for regulated life sciences.
Competitive Position
Veeva's key competitive advantage is its deep, singular focus on life sciences — its products are purpose-built around the specific regulatory, compliance, and workflow requirements of pharma and biotech (e.g., FDA 21 CFR Part 11 validation, GxP compliance), which is difficult for horizontal software vendors to replicate. This vertical focus has let Veeva build a broad, integrated suite spanning commercial, clinical, regulatory, quality, and safety functions, creating cross-sell opportunities and high switching costs once a customer's validated processes are built on the Vault platform. Its customer base includes nearly all of the largest global pharmaceutical companies, giving it a strong reference-driven sales motion and durable, high-retention subscription revenue.
Key risks include customer concentration among a relatively small number of very large pharmaceutical companies (loss of a major customer or a slowdown in life-sciences R&D/commercial spending could disproportionately affect results); increasing competition as Oracle, Salesforce, and other larger, well-capitalized vendors invest more heavily in life-sciences-specific offerings; the complexity and cost of the ended Salesforce partnership transition, which required customers to migrate CRM workloads to Veeva's own platform; general enterprise software risks such as elongated sales cycles with large, bureaucratic pharma customers; and regulatory or industry-wide pressures (drug pricing reform, R&D budget cuts) that could indirectly reduce life sciences IT spending.